A leading cannabis real estate investment trust (REIT) firm has signed a long-term deal with Green Thumb Industries (GTI) (CSE:GTII,OTCQX:GTBIF).

On Monday (February 3), Innovative Industrial Properties (IIP) (NYSE:IIPR) confirmed that its new partnership with the Illinois-based multi-state operator (MSO) will begin with a sale-leaseback transaction for a processing facility in Toledo, Ohio.

This isn’t the first agreement completed between the two firms, as last year the duo came together for a cultivation and processing facility sale-leaseback agreement in Danville, Pennsylvania.

Ben Kovler, GTI’s founder and CEO, said in a statement that the funds for the deal in Ohio will be used for expansion purposes.

“IIP provides a flexible real estate capital solution that effectively addresses our expansion needs at the processing facility in Toledo,” the GTI executive said.

The total agreed sum for the facility is US$7.2 million, given that GTI completes a list of undisclosed improvements to the operation. If the facility work is not completed, IIP will only pay US$2.9 million, according to the joint announcement from the US firms.

“GTI continues to distinguish itself with its cannabis product offerings and dedication to patient experience and right to well-being, providing safe, high quality cannabis products in a compassionate environment,” said Paul Smithers, president and CEO of IIP.

The market offered differing takes for each company on the announcement. Shares of IIP soared at open, and as of 1:30 p.m. EST were trading at US$92.74, representing an increase of 3.7 percent.

On the other hand, GTI shares dragged in Monday’s trading session with a 3.4 percent drop in value, resulting in a price per share of US$12.22.

IIP has quickly embedded itself as a capital solution for cannabis companies facing the harsher realities of the capital markets, thanks to the REIT strategy.

The REIT company has seen this interest reflected in its share price so far this year, experiencing a jump in value of over 20 percent. While most of the cannabis universe has struggled recently, IIP has continued to grow and offer investors access to a cannabis play while remaining compliant with regulations for the New York Stock Exchange.

stock chart for IIP

In a previous interview with the Investing News Network (INN), Smithers said investors feel more comfortable with the company as it adheres strictly to real estate operations. With every deal completed, IIP does not obtain a stake in the cannabis company participant.

“We’re strictly a real estate company and I think there’s a certain group of investors that like that. It’s a little more stability than a company that is perhaps growing,” said Smithers.

MSOs in the US have embraced the REIT model, with fellow MSO Cresco Labs (CSE:CL,OTCQX:CRLBF) completing separate agreements with both IIP and GreenAcreage Real Estate.

“It becomes a higher operating cost that that company will incur for the term of the lease and some of these are 15 years, and they’re not very cheap,” Mike Regan, an analyst with Marijuana Business Daily’s Investor Intelligence, previously told INN. “But that’s still cheaper than going out of business.”

Shares of the REIT company have been added to the recently debuted Medical Cannabis & Wellness UCITS ETF (XETRA:CBDX). The fund trades in Europe and offers investors established cannabis plays with no connection to the recreational space in North America.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less